Andrew Musgrave
Welcome again to ASX Briefs, and in this exclusive interview, we sit down with Professor Thian Chew, the Executive Chair and CEO of Invion Limited, to discuss a transformative quarter for the clinical stage life sciences company. Invion believes the next 12 months will be a particularly exciting period for the company following a series of major announcements in late 2025 and January 2026. These include its expanded global licensing rights, a significant non-dilutive funding deal, and its multiple cancer development pipeline. Thian, thanks for joining me again and welcome back to the ASX Briefs podcast.
Thian Chew
Thanks, Andrew. Very nice to be back.
Andrew Musgrave
Now Thian, it's been a while since we last spoke, but for investors that may be unfamiliar with the company, can you just provide a brief overview?
Thian Chew
Yeah, sure thing. So Invion has a photodynamic therapy technology that's novel, and that means it's a combination of a drug and a and some light. So, the drug itself actually is localized selectively in cancer cells and basically not in healthy cells. So, it's actually just localized there. And then what happens is it's pretty inactive until you shine a certain frequency of light. And what that light does is then creates an oxidation process which kills just the cancer cells. So, it's a very, very precision approach to killing cancers. And on top of that, the second thing it does is it activates the immune response. We've also found that in addition to cancers, it actually works on infectious diseases. So, the same mechanism kills bacteria, fungi, and viruses. So, we have quite a large platform of compounds and applications. So that's in a nutshell what the technology does. If you think about the type of applications, we're in the cancer side, we're already at clinical trial stage. So, we've already done an investigator-led phase two trial in prostate cancer. We are ongoing with a non-melanoma skin cancer trial, and we're working with the Peter McCallum Cancer Centre to prepare for an Ano-Genital cancer, which we're in process on.
Andrew Musgrave
Okay, and you've recently secured a landmark non-dilutive grant from South Korean government's KDDF. So, how significant is this up to $2 million commitment for the development of INV043?
Thian Chew
Yeah, it's a great question. We have a platform technology. We're a relatively small biotech company, so we either focus on a small number of things and ignore everything else, or we partner. And we've been partnering with Hanlim Pharma for the last one, two years, and they've already been funding some preclinical work, so testing our compounds in esophageal cancer and also exploring glioblastoma, brain cancer. This announcement really, really validated our technology because a significant portion of that funding, which is up to $2 million, is actually um funded by the Korean Drug Development Fund, which is a Korean government fund focused on developing biotech. And as a result, it's non-dilutive funding. So essentially it means that we get the R&D and it doesn't, we don't get shareholders diluted by that amount, which is fantastic. And in addition to just the money, what it really validates is that there are external parties, both a pharma company as well as a you know a sort of a national sort of our drug development fund that's actually validated um our technology and believes it's worthwhile to invest those funding. So, we're really excited about where that could take us. The work is focused on esophageal cancer and using an IV route of administration.
Andrew Musgrave
Okay, and can you also discuss the potential addressable market for INV043?
Thian Chew
Yeah, well, you know, the way INV043 localizes in many cancer cells is what's known as the Warburg effect. Cancers like sugars. So, we coded our core molecule with glucose conjugates. And so, lots of different types of cancers will gobble up the INV043. And we've actually shown that in over half a dozen uh cancer models in in mice. So, what that means is that you've got this same technology that can work on multiple cancers. Now, our trial, for example, in skin cancer is in a topical formulation. So, you can actually put that ointment on the skin. What the Hanlim and KDDF esophageal grant will help do for us is to develop an IV formulation. So, what that then means is that we've got both topical as well as IV, which then can be used across a whole number of different ways to administer across a whole number of cancers. And what that means is once we've got that, we can actually use our INV043 across a large number of different cancers. And that's where we can be we can really start getting some exciting data that hopefully will get everyone quite excited about the potential.
Andrew Musgrave
Now, Invion recently secured a perpetual exclusive global license to the Photosoft platform. So, how does this move remove the strategic overhang you mentioned previously?
Thian Chew
Yeah, we've we had a little bit of hair on our company for the last year or two, and I think what that meant was often investors that that we spoke to kind of got distracted by the hair. And one of the big pieces of hair was, you know, we may have this great technology, but previously we only had Asia Pacific, excluding China and Japan as our territory. Most people and most pharma companies and most people in the industry don't really think about that. They think about well, what indication or disease area are you really focused on? And I want to have global rights. Otherwise, it's too confusing, it's too fragmented, who's got who's out who looks after which bit. This global license essentially gives us the opportunity to really be in the driver's seat. We've chosen a number of disease indications, both in cancer as well as infectious diseases, that we think have a lot of potential. And they're the ones we're going to go after, and we've already got global rights. On top of that, we have a lot of freedom now to basically do whatever deal we want to do with freedom without needing to go back to, you know, the licensed saw that might own another part of the world. So, it really takes away some of the shackles. And what it really gives us is this opportunity for our investors and shareholders to focus on what we have, not focus on the complications.
Andrew Musgrave
You've also branched into animal health with Protect Animal Health. What does this partnership say about the versatility of the Photosoft technology?
Thian Chew
We actually have a few hundred novel compounds we developed, actually, mostly during COVID. And INV043 is just one of those compounds. Obviously, if our compounds work on humans and we've already tested it on mice, we've got a decent chance it'll actually work on other animals as well. And so, we teamed up with a listed Taiwanese company called Protect Animal Health. And they are a pet pharmaceutical company. They've got some really, they're really sophisticated. Most of their people have are from a human pharmaceutical background. And what we're working with them on is to test one of our other compounds to take it through the whole drug development process from in vitro work, in viva work, ultimately to companion animal trials. And that will open up a whole new market for us and potentially give us a faster path to commercialization because we're dealing with pet and companion animals, which often have fewer steps to take than a human um sort of uh approval process.
Andrew Musgrave
Okay, now finally, Thian, with a recent $1.3 million capital raise and the 400,000 RD facility in place, what are the key milestones investors should look out for over the next 12 to 18 months?
Thian Chew
Well, you know, now that some of those overhangs are past us, I think the first thing investors should look at is what do we have right now today? So, we've already got a drug that's already or treatment that's already in clinical trials. In fact, it's already in two clinical trials going to a third. That's what we have today. We've got a bunch of, a couple of partners that are funding our programs with non-dilutive funding. And that's really what we have today. And if you look at what we have and you compare it with the comparables, I think you'll find that there's a pretty significant sort of gap right now. So, on top of that, then the investors can say, well, what's coming up next? And I think some of the things include, well, we're currently undergoing our non-melanoma skin cancer trial. We'll continue to recruit more patients, and we will have more results that we'll be announcing on that phase one trial. Ultimately, we'll progress to phase two. So that's one area. The second catalyst would be the Ano-Genital cancer trial that we're doing with Peter McCallum Cancer Centre. That one's a little bit different because it's not only just our photodynamic therapy as it's standalone, but it's actually combining with established immunotherapies. Now, immunotherapies work pretty well. So typically, they talk about a 12% response rate. We got that to 80% in some of our animal models, and that's one of the focus areas for us in this Ano-Genital cancer trial with Peter Mac. So, we're in process of getting internal approvals for it at the Peter Mac. And there could be some essentially announcements and catalysts around formal approvals and getting these trials started, et cetera, et cetera. Now they're the two indications that we're actually investing our funds in. There's a couple of other indications I measured where we're actually not investing any money in it. And one of them is the esophageal cancer work with Hanlim and the Korean Drug Development Fund. And there could be some um catalysts around that over some of the work we're doing right now, which includes potential animal efficacy studies, et cetera, et cetera. On top of that, we have potential catalysts around updates on the pet cancer development process, where we're doing, you know, preclinical work, we're doing some efficacy work, we're getting ready to do some work ultimately in companion animals themselves, which is that the pet equivalent of a clinical trial. And there's a number of those catalysts that could be coming up as well. And again, for the last two, you know, someone else is funding it. And ultimately, we would hope we can do a more formal collaboration, share the upside, which incentives them to invest with us, and establish that we really want to have a partnership model with industry and share the upside. And it also highlights that we're not really a one drug or one treatment company, but we're actually a platform technology with multiple paths to commercialization.
Andrew Musgrave
Okay, Thian. Well, it's been great to chat again and get an update on where the company is at, and we look forward to further updates in the upcoming months.
Thian Chew
Great. Thanks, Andrew. Great speaking with you again.
Andrew Musgrave
That concludes this episode of ASX Briefs. Don't forget to subscribe, and we look forward to catching you on our next episode.